John J Kopchick

This inventor holds 28 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Growth Hormone Research. Top assignees: Ohio University, Abbott Laboratories Corporation, Merck + Co., Inc.. Active years: 1987-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John J Kopchick. Retrieved from https://idiyas.com/inventor/john-j-kopchick

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 11)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.9

ph-index = 11

Forward Citations = 680(Granted Patents)

Location History:

Verona, NJ (US) (1987 - 1989)
Athens, OH (US) (1994 - 2024)

Company Filing History:

Abbott Laboratories Corporation

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2026

Loading Chart...

Areas of Expertise:

FSP27 Compositions

Cancer Treatment

Growth Hormone Antagonists

Peptide Inhibitors

Transgenic Mammals

Free Fatty Acid Regulation

Acromegaly Treatment

Glycoproteins Production

Oligosaccharides

Gene Regulation

Therapeutic Agents

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12751992 - METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS (2026-10-06),

2. 12251421 - Methods for treating cancers using fat specific protein 27 (FSP27) compositions (2025-03-18),

3. 11975044 - Methods for treating cancers using fat specific protein 27 (FSP27) compositions (2024-05-07),

4. 11925674 - Methods for regulating free fatty acid flux using fat specific protein 27 (FSP27) compositions (2024-03-12),

5. 11857602 - Growth hormone antagonist and anti-cancer composition combination therapy (2024-01-02),

6. 11820804 - Peptide-based inhibitors of growth hormone action and methods of use thereof (2023-11-21),

7. 11524986 - Peptide-based inhibitors of growth hormone action and methods of use thereof (2022-12-13),

8. 11473088 - Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down (2022-10-18),

9. 11452763 - Therapeutic pegylated growth hormone antagonists (2022-09-27),

10. 11433117 - Methods for regulating free fatty acid flux using fat specific protein 27 (FSP27) compositions (2022-09-06),

11. 11426445 - Methods for treating cancers using fat specific protein 27 (FSP27) compositions (2022-08-30),

12. 8962811 - Growth hormone and interferon-alpha 2 glycoproteins produced in plants (2015-02-24),

13. 7309572 - Growth hormone-regulatable liver genes and proteins, and uses thereof (2007-12-18),

14. 7060437 - Growth hormone-regulatable brown adipose tissue genes and proteins and uses thereof (2006-06-13),

15. 6858389 - Growth hormone-regulatable liver genes and proteins, and uses thereof (2005-02-22),

Title: The Innovative Journey of John J Kopchick

Introduction: John J Kopchick, a renowned inventor hailing from Athens, OH (US), has made significant contributions to the field of science and technology through his groundbreaking inventions.

Latest Patents: Kopchick holds several patents in the field of biotechnology and pharmaceuticals, with his most recent patent focusing on a novel drug delivery system for targeted cancer therapy.

Career Highlights: With a distinguished career spanning over three decades, Kopchick has served as a leading researcher at various prestigious institutions, pioneering advancements in the fields of molecular biology and genetics.

Collaborations: Throughout his career, Kopchick has collaborated with top scientists, researchers, and pharmaceutical companies to further develop and commercialize his innovative inventions, leading to impactful contributions in the healthcare industry.

Conclusion: John J Kopchick's relentless pursuit of innovation and his commitment to scientific excellence have solidified his position as a trailblazing inventor in the realm of biotechnology and pharmaceuticals.

Profile summary based on public USPTO records.